Research programme: microbiome-based cancer therapeutics - CJ Bioscience
Latest Information Update: 30 Aug 2023
At a glance
- Originator CJ Bioscience
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 02 Jun 2023 Preclinical trials in Cancer in South Korea (unspecified route) (CJ Bioscience pipeline, June 2023)
- 02 Jun 2023 Pharmacodynamics data from a preclinical trial in cancer released by CJ Bioscience (CJ Bioscience pipeline, June 2023)